We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+131.02%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$143M
AUM Growth
+$40.4M
Cap. Flow
+$11.7M
Cap. Flow %
8.18%
Top 10 Hldgs %
81.78%
Holding
32
New
7
Increased
10
Reduced
6
Closed
9

Top Buys

1
AFMD
Affimed
AFMD
+$10.5M
2
ADMS
Adamas Pharmaceuticals
ADMS
+$7.13M
3
AMRN
Amarin Corp
AMRN
+$5.92M
4
EOLS icon
Evolus
EOLS
+$5.57M
5
APVO icon
Aptevo Therapeutics
APVO
+$4.98M

Top Sells

1
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$10.9M
2
ENTA icon
Enanta Pharmaceuticals
ENTA
+$7.8M
3
LGND icon
Ligand Pharmaceuticals
LGND
+$2.98M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.95M
5
ALIM
Alimera Sciences
ALIM
+$1.55M

Sector Composition

1 Healthcare 92.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
1
Amarin Corp
AMRN
$292M
$33.3M 23.18%
77,565
+15,587
+25% +$5.92M
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$25.7M 17.94%
3,000,000
-825,903
-22% -$2.95M
AFMD
3
DELISTED
Affimed
AFMD
$11M 7.66%
401,016
+393,166
+5,008% +$10.5M
OXFD
4
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$10.5M 7.3%
630,862
-50,950
-7% -$826K
ADMS
5
DELISTED
Adamas Pharmaceuticals
ADMS
$8.49M 5.92%
2,241,239
+1,490,227
+198% +$7.13M
NEOS
6
DELISTED
Neos Therapeutics, Inc
NEOS
$7.34M 5.11%
4,858,889
+356,588
+8% +$535K
CTIC
7
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$5.93M 4.14%
3,755,000
+43,001
+1% +$40.7K
XOMA
8
DELISTED
Xoma
XOMA
$5.48M 3.82%
200,667
-29,534
-13% -$661K
OPNT
9
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$4.81M 3.36%
334,272
+20,199
+6% +$294K
EOLS icon
10
Evolus
EOLS
$377M
$4.81M 3.35%
+394,890
New +$5.57M
APEN
11
DELISTED
Apollo Endosurgery, Inc.
APEN
$4.71M 3.28%
1,651,333
+188,145
+13% +$545K
CPIX icon
12
Cumberland Pharmaceuticals
CPIX
$102M
$4.62M 3.22%
896,170
+35,721
+4% +$189K
HTGM
13
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$3.34M 2.33%
26,436
-5,732
-18% -$776K
NVLN
14
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$2.76M 1.92%
3,909,207
+205,787
+6% +$146K
APVO icon
15
Aptevo Therapeutics
APVO
$5.91M
$2.73M 1.91%
+1
New +$4.98M
GYRE icon
16
Gyre Therapeutics
GYRE
$675M
$2.09M 1.46%
+40,972
New +$1.72M
CHMA
17
DELISTED
Chiasma, Inc. Common Stock
CHMA
$911K 0.64%
183,660
+73,917
+67% +$385K
SBBP
18
DELISTED
Strongbridge Biopharma plc.
SBBP
$903K 0.63%
+431,853
New +$828K
SCYX icon
19
SCYNEXIS
SCYX
$42.4M
$555K 0.39%
+7,617
New +$628K
IDXG
20
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
$472K 0.33%
94,385
-21,653
-19% -$140K
ACET icon
21
Adicet Bio
ACET
$75.9M
$122K 0.09%
+730
New +$370K
ACER
22
DELISTED
Acer Therapeutics Inc
ACER
$80K 0.06%
20,000
-94,175
-82% -$320K
DMAC icon
23
DiaMedica Therapeutics
DMAC
$393M
– –
-13,705
Closed -$28K
DRRX
24
DELISTED
DURECT Corp
DRRX
– –
-10,000
Closed -$184K
ENTA icon
25
Enanta Pharmaceuticals
ENTA
$400M
– –
-129,867
Closed -$7.8M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Stonepine Capital Management held 32 positions worth $143M, up 39% from $103M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Stonepine Capital Management deployed $11.7M of net new capital in Q4 2019, opening 7 new positions and adding to 10 existing holdings. Its largest new stake was Evolus: 394,890 shares worth $4.81M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 96% a quarter earlier.

On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $2.95M trimmed.

  • Stonepine Capital Management's largest Q4 2019 buy was Evolus: 394,890 shares worth $4.81M.
  • Stonepine Capital Management added most to Affimed in Q4 2019, an estimated $10.5M increase.
  • Stonepine Capital Management's biggest Q4 2019 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $2.95M.
  • Stonepine Capital Management fully exited BioDelivery Sciences International, Inc. in Q4 2019, selling an estimated $10.9M.
  • Stonepine Capital Management's ten largest holdings make up 82% of its $143M portfolio in Q4 2019.
  • Stonepine Capital Management opened 7 new positions and closed 9 in Q4 2019.
  • Stonepine Capital Management's portfolio value rose 39% quarter-over-quarter to $143M.

Based on Stonepine Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.